PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 113, Issue 26, Pages 7124-7129
Publisher
Proceedings of the National Academy of Sciences
Online
2016-06-07
DOI
10.1073/pnas.1521738113
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance
- (2016) Richard Marcotte et al. CELL
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins
- (2015) Dennis L. Buckley et al. ACS Chemical Biology
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?: Figure 1.
- (2015) C. Sprenger et al. ANNALS OF ONCOLOGY
- Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes
- (2015) D. Xu et al. CANCER RESEARCH
- Abstract 2625: Targeting prostate cancer stem cells (CSCs) with the novel BET bromodomain (BRD) protein inhibitor OTX015
- (2015) Gianluca Civenni et al. CANCER RESEARCH
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
- (2015) Y. Yamamoto et al. CLINICAL CANCER RESEARCH
- Prime time for PROTACs
- (2015) Raymond J Deshaies Nature Chemical Biology
- Catalytic in vivo protein knockdown by small-molecule PROTACs
- (2015) Daniel P Bondeson et al. Nature Chemical Biology
- Are androgen receptor variants a substitute for the full-length receptor?
- (2015) Ji Lu et al. Nature Reviews Urology
- Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
- (2015) Siu Chiu Chan et al. NUCLEIC ACIDS RESEARCH
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.
- (2015) Anastasia Wyce et al. Oncotarget
- Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
- (2015) Bo Cao et al. Oncotarget
- Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer
- (2015) Yuanyuan Qu et al. Scientific Reports
- Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- Evolution of androgen receptor targeted therapy for advanced prostate cancer
- (2014) Yien Ning Sophia Wong et al. Nature Reviews Clinical Oncology
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
- (2014) Jessica E. Bolden et al. Cell Reports
- The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer
- (2014) Cynthia C. T. Sprenger et al. Hormones & Cancer
- Castration-resistant prostate cancer: latest evidence and therapeutic implications
- (2014) Daniel L. Suzman et al. Therapeutic Advances in Medical Oncology
- The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor
- (2014) Jeanny B. Aragon-Ching Frontiers in Oncology
- Advances in prostate cancer treatment
- (2013) Dominic Trewartha et al. NATURE REVIEWS DRUG DISCOVERY
- Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
- (2013) T Karantanos et al. ONCOGENE
- Abstract 3457: Galectin-1 suppression enhances combined anti-EGFR and radiation-therapy of NSCLC
- (2012) Michael Siedow et al. CANCER RESEARCH
- Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
- (2012) Dennis L. Buckley et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
- (2011) Nicolas Mottet et al. EUROPEAN UROLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of TMPRSS2-ERG Gene Fusion in Negative Regulation of PSMA Expression
- (2011) Lihong Yin et al. PLoS One
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
- (2009) William P Harris et al. Nature clinical practice. Urology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now